IOF Positions and Statements

El documento, publicado conjuntamente por siete organizaciones europeas e internacionales, identifica los factores de riesgo de fractura en pacientes tratados con inhibidores de la aromatasa (IA), y describe las estrategias clave de manejo para ayudar a prevenir la pérdida ósea y fracturas relacionadas. Read more
Although progressive muscle loss is a natural part of ageing, sarcopenia is generally identified when muscle mass and muscle function falls below defined thresholds. Sarcopenia’s impact can be enormous as it affects mobility, balance, risk of falls and fractures, and overall ability to perform tasks of daily living. Given the ageing of populations worldwide, public health and clinical... Read more
Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving... Read more
calcium supplement tablets
An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF) has reviewed the evidence for the value of calcium supplementation, with or without vitamin D supplementation, in healthy musculoskeletal ageing. Read more
A new review by the International Osteoporosis Foundation (IOF) Chronic Inflammation and Bone Structure (CIBS) Working Group concludes that early and aggressive treatment of Rheumatoid Arthritis (RA) with biologic drugs, specifically biological disease-modifying anti-rheumatic drugs (DMARDs), may be most effective in halting progressive bone loss in patients with RA. Read more
Una revisión bibliográfica llevada a cabo por el Grupo de Trabajo sobre Inflamación Crónica y Estructura Ósea (CIBS) de la Fundación Internacional de Osteoporosis (IOF) concluyó que el tratamiento temprano y agresivo de la AR con agentes biológicos, particularmente, aquellos anti-reumáticos que modifiquen biológicamente la enfermedad (DMARDs), podría ser más efectivo para la detención de la... Read more
Below is a Statement issued by IOF to the BMJ in response to: Clinical assessment and management of multimorbidity: summary of NICE guidance. Farmer et al, BMJ 2016; 354: i4843 Read more
Recent research has shown that bone health is compromised in people with diabetes, resulting in a significantly higher risk of fragility fracture. Read more
The FRAX Fracture Risk Assessment Tool is a resource developed for the calculation of an individual’s 10-year probability of hip fracture and a major osteoporotic fracture based on specific clinical risk factors, with or without bone mineral density (BMD) values. Read more
A myth which often re-surfaces in media reports is that milk may not be beneficial to bone health. Bone health experts are concerned that this may be causing confusion among the general public and causing many people to avoid milk and dairy foods unnecessarily – when in fact they are among the best sources of bone-healthy nutrients. Read more


Subscribe to IOF Positions and Statements